7 results about "Immune network" patented technology

The present disclosure relates to methods for testing the health of a subject's immune system and treating the subject based on the condition of the immune system. In particular, disclosed herein is a method comprising the steps of obtaining a sample of blood from the subject, reverse transcribing DNA from RNA in the sample; amplifying all seven chains of T and B cell receptors in the DNA sample using multiplex PCR to form amplicons; sequencing the amplicons to generate a sequencing library; identifying nodetypes, clonotypes, v genes, d genes, and j genes and corresponding read counts in the sequencing library; performing the foregoing steps using two or more healthy samples to form a consensus reference pool; identifying the number of nodetypes associated with each V gene sequence in the consensus reference pool and in the subject's sequencing library; comparing the number of nodetypes for each V gene in the consensus reference pool and the subject's sequencing library; and treating the subject if the number of nodetypes is significantly less than the number of nodetypes for V genes in the consensus reference pool. The disclosed method is able to identify gaps in an individual's immune system and treat that individual to improve the diversity of the individual's immune response.

This invention relates to the fields of artificial intelligence and big data processing, specifically disclosing a method for constructing high-dimensional user profiles based on multi-source data fusion and dynamic updates. This method constructs an initial high-dimensional feature vector, introduces an immune mechanism to identify "self" and "non-self" behaviors, establishes a dynamic antibody library with a lifecycle, and combines clonal selection, high-frequency mutation, and natural apoptosis mechanisms to achieve adaptive evolution of the profile. It also constructs a cross-user immune network, utilizes common group behaviors to generate regulatory factors to correct individual biases, and integrates adversarial attack detection, version management, and viability assessment modules. Through the above technical solutions, this invention improves the accuracy, timeliness, and anti-interference capability of user profiles, providing highly reliable data support for precision marketing, intelligent recommendation, and risk prevention and control.

The application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis belongs to the field of biomedical technology. This invention addresses the limitations of existing treatments for inflammatory bowel disease (IBD), which suffer from limited efficacy, significant side effects, and difficulty in targeting and repairing the intestinal immune barrier. It provides the application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis. This recombinant ultra-high molecular weight hyaluronic acid can activate the intestinal IgA-producing immune network, regulate inflammation-related genes, and repair the physical and immune barriers of the colonic mucosa, thus exhibiting a superior protective effect against colitis compared to conventional hyaluronic acid, providing a new candidate drug for the treatment of IBD.

The invention relates to the technical field of medical treatment, in particular to a soluble microneedle patch and application thereof in vaccine delivery. The soluble micro-needle patch creatively adopts a non-uniformly arranged'core-shell-crown 'structure micro-needle array, comprises a high-density central area and a low-density edge area, cooperatively activates a skin immune network through differentiated puncture depth and density, has three advantages of painless and efficient delivery, high room temperature stability and high immune synergy, and can be applied to the field of medical treatment. And the preparation method adopts a low-temperature centrifugation-freeze drying integrated process, is suitable for various vaccine types such as mRNA, protein and the like, and provides an autonomous inoculation solution for sudden epidemic situations and large-scale immunization.

The invention discloses a composition helpful for relieving and improving anxiety type insomnia and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 1.5-2.5 parts of poria cocos, 1.5-2.5 parts of lily, 1.5-2.5 parts of spina date seeds, 0.5-0.7 part of rhizoma polygonati, 0.4-0.6 part of lucid ganoderma, 0.4-0.6 part of angelica sinensis, 0.4-0.6 part of codonopsis pilosula, 0.4-0.6 part of polygala tenuifolia, 0.4-0.6 part of cortex albiziae, 0.3-0.5 part of liquorice and 0.2-0.3 part of coptis chinensis. The invention solves the problems that the existing medicine for relieving and improving anxiety type insomnia is easy to cause tolerance, dependence and even withdrawal reaction in the use process, and is difficult to fundamentally regulate the unbalance state of nerves, internal secretion and immune networks, and the treatment effect is reduced.

The invention discloses a traditional Chinese medicine navel application agent for activating an abdominal cavity immune network and a preparation method thereof, through specific compatibility of 11 pungent and warm medicines (including five medicines for resolving dampness with aromatics, five medicines for warming the interior and one medicine for astringing the intestine), and in combination with a superfine grinding technology (the particle size is less than or equal to 30 microns) and a beta-cyclodextrin inclusion process, the transdermal absorption rate of the medicines is increased to 3-5 times that of common navel therapy. Animal experiments show that the preparation can increase the phagocytic rate of macrophages in the abdominal cavity of a mouse by 32.7%, the CD4 + / CD8 + ratio of T lymphocytes is recovered from 1.2 to 1.8 + / -0.2, and the slgA concentration of mucous membranes is increased by 2.3 times. Clinical observation shows that the effective rates for diarrhea, stomachache and vomiting symptoms caused by deficiency-cold of spleen and stomach of children within 24 hours respectively reach 90.2%, 85.6% and 80.4%, and liver and kidney dysfunction is not found.

The invention provides application of combined use of cerium ions and luteolin in preparation of an external medicine for treating specific dermatitis. The invention also provides a Lut-Ce-MOF nanoparticle, which is prepared by synthesizing the amino functionalized zirconium-based metal organic framework UIO-66-NHH loaded cerium ions and luteolin by a solvothermal method, and then preparing the nanoparticle. The invention also provides a Lut (at) M / C-O hydrogel. The Lut (at) M / C-O hydrogel is prepared from the Lut (at) Ce-MOF nanoparticles, carboxymethyl chitosan (CMCS) and trihydroxymethyl aminomethane-oxidized hyaluronic acid (OHT) as raw materials. The hydrogel provided by the invention can provide a long-acting moisturizing microenvironment, passively promote repair and a more comprehensive immunoregulation network, can also avoid the problem of drug resistance of antibiotics, and is a comprehensive strategy of immunoregulation, physical barrier and component antibiosis.